My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Tandem Diabetes Care, Inc. - Common Stock (NQ:TNDM)

19.17 +0.23 (+1.21%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tandem Diabetes Care, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday ↗

April 29, 2024

Via Benzinga

TANDEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Tandem Diabetes Care, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

April 23, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Cracking The Code: Understanding Analyst Reviews For Tandem Diabetes Care ↗

April 23, 2024

Via Benzinga

1 Beaten-Down Stock That Could Make You Richer ↗

April 07, 2024

Don't give up on this healthcare stock too soon.

Via The Motley Fool

What 4 Analyst Ratings Have To Say About Tandem Diabetes Care ↗

April 03, 2024

Via Benzinga

Why Tandem Diabetes Care Stock Popped Today ↗

February 22, 2024

Tandem Diabetes climbed as investors focused on its strong outlook for the coming year.

Via The Motley Fool

3 Weight-Loss ETFs to Profit From the Obesity Drug Boom ↗

April 17, 2024

Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.

Via InvestorPlace

Topics ETFs

Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024

April 09, 2024

From Tandem Diabetes Care, Inc.

Via Business Wire

Why Tandem Diabetes Care Stock Was Zooming Higher Today ↗

March 26, 2024

One product in particular could juice the company's fundamentals, a pundit believes.

Via The Motley Fool

Stocks Inch Higher, Tesla Rebounds, Bitcoin Holds Below $70,000: What's Driving Markets Tuesday? ↗

March 26, 2024

Wall Street is set to break a two-day losing streak on Tuesday, as major indices trended positively during midday trading in New York. The S&P 500 saw a modest uptick of 0.3% for the day, with the Dow...

Via Benzinga

Topics Stocks

Tandem Diabetes Care: Q4 Earnings Insights ↗

February 21, 2024

Via Benzinga

Earnings Scheduled For February 21, 2024 ↗

February 21, 2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

Via Benzinga

2 Beaten-Down Stocks That Are Worth Buying ↗

February 04, 2024

Don't be too quick to ignore these stocks.

Via The Motley Fool

Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday ↗

March 26, 2024

U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday.

Via Benzinga

Topics Stocks

Shhh! 7 Small-Cap Stocks That Can Double by 2025 ↗

March 20, 2024

Small-cap stocks have been hot and these shares discussed here are likely to heat up and double over the next year.

Via InvestorPlace

Parexel Announces CEO Succession Plan

March 18, 2024

Chief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024; Mr. Macdonald to retire as CEO and continue on the Board of Directors through Dec. 31, 2024

From Parexel International LLC

Via GlobeNewswire

Tandem Diabetes Care Stock Belongs On Your Watchlist As RS Rating Jump Higher ↗

March 11, 2024

On Monday, Tandem Diabetes Care stock received an upgrade to its Relative Strength (RS) Rating, from 68 to 78.

Via Investor's Business Daily

Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029

March 06, 2024

From Tandem Diabetes Care, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 04, 2024

Via Benzinga

Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes

March 04, 2024

From Tandem Diabetes Care, Inc.

Via Business Wire

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 05, 2024

Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.

Via Benzinga

DexCom: A Winner In Diabetes Management ↗

February 25, 2024

Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820...

Via Talk Markets

Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday ↗

February 23, 2024

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday.

Via Benzinga

Topics Stocks

Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 23, 2024

Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results.

Via Benzinga

Tandem Diabetes Care Inc. (NASDAQ: TNDM) Making Surprising Moves in Thursday Session

February 22, 2024

Via Investor Brand Network

Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance

February 21, 2024

From Tandem Diabetes Care, Inc.

Via Business Wire

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

February 13, 2024

From Tandem Diabetes Care, Inc.

Via Business Wire

Tandem Diabetes Care Announces Upcoming Conference Presentations

February 08, 2024

From Tandem Diabetes Care, Inc.

Via Business Wire

7 Tremendous Dividend Stocks With Double-Digit 5-Year Growth Rates ↗

February 07, 2024

When it comes to buying dividend stocks, investors should seek out companies that consistently and repliably grow their payout over time.

Via InvestorPlace

Abbott Laboratories Surpasses Q4 Sales Expectations, Despite Dip In COVID-19 Testing Demand ↗

January 24, 2024

Abbott Laboratories exceeds expectations with Q4 sales of $10.24B, showcasing resilience despite softer demand for COVID-19 testing. CEO anticipates continued growth in 2024.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.